Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2011

View Archived Issues

Safety data presented from clinical evaluation of BIBF-1120 in hepatocellular carcinoma

New qRT-PCR-based microRNA profiling technique serves as diagnostic tool in CTCL

Ardea Biosciences provides update on lesinurad development

Results presented from several clinical studies assessing zonisamide in partial epilepsy

Bristol-Myers Squibb describes new chemokine CCR2 receptor antagonists

Boehringer Ingelheim Pharma patents novel therapies for HIV

New nitric oxide donors claimed for diabetes-associated neuropathic pain

Phase I/II data presented on DAC-060 in nonmelanoma skin cancer

Novartis develops novel cyclin-dependent kinase inhibitors

New glycoprotein-Ig fusion proteins generated to elicit immunity against HCV

BioLineRx signs agreement with Tel Aviv University for BL-7050

Pharnext gathers funds for further development of Pleodrug for Charcot-Marie-Tooth disease

Novel recombinant proteins catalyze tRNA aminoacylation

Trophos completes enrollment in pivotal study of olesoxime

Pluristem's PLX cells show promise in preclinical studies

Repros Therapeutics presents phase II data on low-dose Proellex

FDA clears DelMar Pharmaceuticals' IND for phase I/II VAL-083 trial

Bristol-Myers Squibb acquires Amira Pharmaceuticals

FDA committee issues recommendation on rivaroxaban to prevent stroke and systemic embolism in AF

NeurogesX submits sNDA for Qutenza to FDA

Alchemia opens recruitment in phase II HA-irinotecan trial

Spherix combination treatment reduces VLDL and LDL in preclinical study

ME-143 enters clinical development

HUYA Bioscience partners with Chinese university

Enterologics completes acquisition of BioBalance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...